Objectives: To identify the risk factors associated with Candida auris candidaemia, as this fungus now poses a global threat.
Introduction
Infection due to Candida auris has emerged as an important challenge in the management of patients admitted to ICUs in India due to its outbreak potential, multidrug resistance and associated high mortality. Since the first report of ear-canal infection by C. auris in Japan in 2009, 1 candidaemia due to this yeast has been reported from three continents with a large number of cases from India having been noted. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The phenotypic and genotypic characteristics of the isolates from India, 2, 3 Kuwait 4 and South Africa 5 were similar and differed from those of Japanese 1 and Korean 6, 7 isolates. Within India, the isolates were clonal in origin, even among hospitals located far apart. 3 These Indian isolates had reduced susceptibility to antifungals, particularly triazoles. To identify the infection early, it is important to study the risk factors associated with C. auris candidaemia as opposed to other Candida species. We were in the unique position of possessing detailed clinical data and the isolates of 1400 candidaemia cases from a prospective study conducted over 27 ICUs across India. 10 The present study was a subgroup analysis and comparison of the clinical details of C. auris and non-auris candidaemia cases to identify the risks associated with C. auris candidaemia.
V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Materials and methods

Study design, settings and definitions
Previously reported clinical data from ICU-acquired candidaemia cases identified between April 2011 and September 2012 in 27 medical and surgical ICUs across India were retrieved. 10 A case of ICU-acquired candidaemia was defined as the isolation of Candida species from blood cultures obtained .48 h after ICU admission or , 48 h after discharge from an ICU. Patients already diagnosed with candidaemia before ICU admission or those transferred from another ICU with a positive culture for any yeast infection were excluded from the study. Prior antifungal exposure was defined as empirical or prophylactic therapy with antifungals within 30 days prior to the diagnosis of candidaemia. Outcome was determined 30 days after onset of candidaemia and cure was considered complete microbiological resolution. A death attributed to candidaemia was ascertained by the treating physician independently on the basis of clinical judgement and microbiology reports. The detailed study design, definition and data collection were described in our earlier report. 10 Both adult and paediatric cases were included in the present study. The phenotypic and molecular characterizations were performed at the national reference centre (Postgraduate Institute of Medical Education and Research, Chandigarh, India).
Ethics
The study was cleared by the respective ethics committees of the participating centres.
Microbiology
The isolates were phenotypically characterized based on morphology on corn meal agar (CMA), growth at different temperatures (37, 40, 42 and 45 C) and in the presence of 0.01% or 0.1% cycloheximide, assimilation of a panel of 14 sugars, and fermentation of D-glucose, D-maltose, sucrose and L-lactose. The identity of all C. auris isolates was confirmed by sequencing the internal transcribed spacer (ITS) region and the D1/D2 region of the large subunit (28S) of the ribosomal DNA.
14 Molecular typing of isolates (n " 51) was performed by amplified fragment length polymorphism (AFLP) according to our earlier protocol with minor modifications (see Supplementary methods available as Supplementary data at JAC Online). 15 Antifungal susceptibility testing of C. auris isolates with amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, anidulafungin and micafungin was performed by broth microdilution using the CLSI M27-A3 guidelines. 16 As the breakpoints for C. auris were not defined, the breakpoints suggested for yeast in CLSI M27-S3 were used to interpret the MICs for this new yeast, and for other Candida species CLSI M27-S4 was followed. 17 For amphotericin B, MIC . 1 mg/L was considered resistant. Multidrug resistance was defined as resistance to two or more classes of antifungals.
Comparison of C. auris and non-auris candidaemia cases
The demographic and clinical data of patients with C. auris and nonauris candidaemia cases were compared. Separately, data of C. auris were compared with five major isolated species, namely Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsilosis and Candida krusei.
Statistical analysis
While comparing C. auris and non-auris candidaemia cases, continuous variables were expressed as mean or medians and IQRs whereas categorical variables were described as frequencies and percentages. were neonates (4 were premature), and 6 were infants. Underlying co-morbid illness included pulmonary (n " 30, 40.5%), renal (n " 16, 21.6%), cardiovascular (n " 15, 20.3%), gastrointestinal (n " 7, 9.5%) and liver (n " 5, 6.8%) diseases. Among underlying respiratory illness, pneumonia was the common presentation (n " 11, 36.7%) followed by chronic obstructive pulmonary disease (n " 3, 10.0%) and acute respiratory distress syndrome (n " 3, 10.0%). Neutropenia was noted in two (2.7%), malignancy in six (8.1%) and other immune-deficient conditions in four (5.4%) patients. The mean APACHE II score at admission was 14.2+5.17 in those patients. A sizeable number of C. auris patients received medical intervention in the ICU including urinary catheterization (n " 56, 75.7%), central venous catheterization (n " 53, 71.6%), post-operative drainage catheter (n " 25, 33.8%) and total parenteral nutrition (n " 15, 20.3%). Outcome of antifungal treatment could be evaluated in 48 (64.9%) patients. The majority of those patients [32 (66.6%)] received azoles, including fluconazole in 27 (56.2%) patients; amphotericin B deoxycholate was prescribed in 11 (22.9%) and echinocandins in 5 (10.4%) patients. The all-cause 30 day crude and attributable mortality in C. auris candidaemia patients were 41.9% and 27%, respectively, whereas the crude and attributable mortality for C. tropicalis, C. albicans, C. parapsilosis, C. krusei and C. glabrata were 35.4% and 24.5%, 37.5% and 25.6%, 31.9% and 18.4%, 23.7% and 10.5%, and 43.2% and 24.3%, respectively.
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Comparison of C. auris and non-auris candidaemia cases
Comparisons by bivariate analyses of C. auris with non-auris (together), C. tropicalis, C. albicans, C. parapsilosis, C. krusei and C. glabrata individually are provided in Table 1 and Tables S1-S6, . The presence of a central venous line was not significantly associated with C. auris candidaemia cases (65% versus 71%, P " 0.152). However, the duration of central line in days was significantly higher in C. auris-infected patients compared with non-auris candidaemia patients (median 10.5, IQR 5-27 days versus median 8, IQR 4-14 days, P " 0.018). Total parenteral nutrition (TPN) was significantly associated with C. auris candidaemia compared with non-auris candidaemia patients (20.3% versus 12.1% P " 0.036). On multivariate logistic regression analysis, admission to north India ICUs (P " 0.012) and public-sector hospital (P " 0.006), underlying respiratory illness (P " 0.002), vascular surgery (P " 0.048), prior antifungal exposure (P , 0.001) and low APACHE II score (P " 0.007) were significantly associated with C. auris infection compared with five other non-auris candidaemia cases (Table 2) .
Identification, typing and antifungal susceptibility testing of C. auris isolates C. auris could grow at 42 C, but failed to grow in the presence of 0.01% or 0.1% cycloheximide. The isolates could ferment maltose. The sequencing of the ITS and D1/D2 regions of the 28S subunit of ribosome revealed 99%-100% homology with C. auris; .99% homology with an unrelated C. auris strain (HE797774.1) and an earlier reported isolate from New Delhi (KC692063.1), and 100% homology with Korean ear isolates (EU881961.1). AFLP results showed that the majority of the C. auris isolates (45/51, 88.23%) had an identical (99%-100%) fingerprint, suggesting the clonal nature of the isolates. Six isolates (11.8%) clustered separately from the main clone and varied between 3% and 10.6% (Figure 1) .
The results of in vitro antifungal susceptibility testing of C. auris isolates are presented in Table 3 . Antifungal resistance was noted to amphotericin B (n " 10, 13.5%), fluconazole (n " 43, 58.1%), voriconazole (n" 2, 2.7%), itraconazole (n " 3, 4.3%) and caspofungin (n " 7, 9.5%). Multidrug resistance was noted in 12 (16.2%) isolates, of which 11 (91.7%) showed resistance across two antifungal classes and one isolate showed resistance across three antifungal classes (polyene, azoles, echinocandins).
Discussion
The present study depicts the prevalence, patient characteristics and risk factors of a large number (n " 74) of C. auris candidaemia cases in ICUs across India. The yeast was isolated from 19 of 27 ICUs. The comparison between patient details of C. auris and non-auris candidaemia indicated the association of C. auris with five independent risk factors namely admission to ICUs of north Indian hospitals, admission to public-sector hospitals, namely respiratory disease, vascular surgery and prior antifungal exposure even in patients with a low APACHE II score at admission. However, variation was noted in the number of those risk factors when C. auris was compared with five other Candida species individually.
In earlier studies, with small numbers of cases in undefined populations, the prevalence of C. auris candidaemia was reported to be 0.04% in the UK 9 and 30% in India. 2 The present study dealt with the largest number of C. auris candidaemia cases yet examined. The prevalence of 5.3% in our study is, therefore, a more accurate estimation and ranks C. auris fifth among all candidaemia cases in Indian ICUs. 10 The infection was first noted in Delhi, 18 and then spread across the country, though higher prevalence was noted in north Indian public-sector hospitals. It was difficult to identify the reason for the higher prevalence of C. auris candidaemia in north India from the present study, as the report was only a subgroup analysis of a prior study and data on infection control practices or other possible reasons for higher rates of candidaemia in ICUs were not captured. From north India, five private-sector and four public-sector hospitals were included in the study. The overcrowding of patients in public-sector hospitals due to healthcare cost constraints, and possible compromise in infection control practices in those hospitals, may be responsible for the higher rate of C. auris candidaemia.
C. auris candidaemia was diagnosed even in patients exhibiting lower morbidity (APACHE II score 14.29+5.18), though C. auris was not recognized as a highly virulent organism compared with C. albicans and C. tropicalis in a recent study. 19 Hyphal filamentation, a possible major virulence factor in pathogenic Candida species, is also absent in C. auris. The presence of C. auris candidaemia in lower-morbidity patients may be due to multiple medical interventions in those patients during their ICU stay. TPN, urinary catheterization, post-operative drain placement and vascular surgery were significant variables associated with C. auris candidaemia in the present study. In a recent outbreak of 18 cases of C. auris in critically ill patients admitted to an ICU, all of them had been exposed to antibiotics and a considerable number to multiple invasive procedures such as central venous catheterization (100%) and surgery (55.6%) before acquisition of C. auris infection. 20 The significant association of longer duration of central venous lines, urinary catheterization, post-operative drainage in our patients, and the relatively late acquisition of infection after ICU admission support the hypothesis of nosocomial transmission of C. auris in ICUs. However, a systematic prospective multicentre study is required to identify the source of the agent in the hospital and elucidate the transmission mechanism. Earlier reports noted urinary catheterization in 83%-91.6% of cases, 2,3,11 central venous catheterization in 42%-94%, 2,3,11 broad-spectrum antibiotic use in 75%-100%, 3, 4 total parenteral nutrition in 47%-100%, 2,7,11 longer ICU stay in 58%-91.6% 2, 3 and surgery in the last 30 days in 58.3%-66.6% 2,7 for patients with C. auris candidaemia. However, Rudramurthy et al.
no statistical correlation was attempted in those studies, possibly due to the small number of patients studied.
The incidence of C. auris candidaemia was significantly higher in patients who had previous exposure to fluconazole or echinocandin compared with that in patients with susceptible species such as C. albicans and C. tropicalis. The difference was not significant with relatively resistant species such as C. krusei, C. glabrata and C. parapsilosis. These findings suggest that The majority (6/7) were exposed to caspofungin and only one patient received anidulafungin.
C. auris candidaemia in Indian ICUs
JAC antifungal exposure exerted selective pressure for C. auris. Prior antifungal exposure was noted in 33%-58% of patients in earlier studies. 3, 5, 6 The present study predicts a model to identify susceptible populations. Patients with sepsis, undergoing invasive management for longer periods and exposed to antifungal agents should be investigated for C. auris candidaemia in India. Although the presence of respiratory illness was a significant risk factor in our model, there were no significant associations noted with mechanical ventilation or tracheostomy or antibiotic use.
The identification of C. auris in a routine laboratory may be difficult, as some automated identification systems misidentify this agent as Candida haemulonii/Candida famata/Candida sake or Rhodotorula glutinis. 3, 5, 6, 8, 21 Our C. auris isolates could grow at 42 C, but failed to grow in the presence of 0.01% or 0.1% cycloheximide. These characteristics could help to presumptively differentiate C. auris from C. haemulonii in the majority of Indian laboratories, as they rely on conventional phenotypic identification and are not equipped with DNA sequencers or matrix MALDI-TOF biotypers. In our earlier study, C. auris isolates could be identified by MALDI-TOF after improving the database. 22 Similar observations were made by other studies. 21, 23, 24 MALDI-TOF can be used in routine laboratories for rapid identification of C. auris isolates.
The clonality of Indian isolates and the difference from Korean and Japanese isolates was reported earlier. 3 The AFLP fingerprinting in the present study confirmed the clonality of Indian C. auris isolates. Clustering of cases by country was reported, indicating geographical strain variability. 3, 9, 13, 23, 24 Although the AFLP method may not be as discriminatory as whole genome sequencing, it is one of the more highly discriminatory typing techniques, and can compare genomic characteristics of isolates quickly.
The 30 day crude and attributable mortality of 41.9% and 27% respectively in C. auris candidaemia were higher compared with non-auris candidaemia. The findings are similar to earlier studies on C. auris candidaemia with overall mortality ranging from 28.0% to 50.0%. 2, 3, 20 Owing to its decreased susceptibility to azoles, it is difficult to treat C. auris candidaemia cases. [2] [3] [4] 6, 8, 25, 26 C. auris isolates had high MICs even of isavuconazole and posaconazole. 3 A large number of isolates (58.1%) in the present study showed resistance to fluconazole. The patients with C. auris infection also had higher fluconazole exposure prior to candidaemia diagnosis. The emergence of a few isolates with high MICs of caspofungin (9.5%) is a major concern, as an echinocandin is the first line of choice to treat candidaemia in the ICU. 27 However, due to the high variability of in vitro susceptibility testing results for caspofungin by the CLSI method, these results need to be interpreted with caution. 28 Of our isolates, 13% had an MIC .1 mg/L against amphotericin B. A similar observation was noted in Korean isolates; 5 whereas 50% of the isolates from Venezuela showed high amphotericin B MIC (.1 mg/L). 20 All these studies indicate that the in vitro susceptibility of C. auris to amphotericin B varies widely. The present study also demonstrated cross-resistance to the triazole group of antifungal agents in 14.8% of the isolates and multidrug resistance in 16.2% of isolates. The present study has certain limitations, as the study was not primarily aimed at evaluating the epidemiology of C. auris candidaemia. It is a subgroup analysis of a previously conducted study. The study did not look into colonization or the possible source of the agent in the C. auris candidaemia in Indian ICUs JAC environment and the transmission mechanism. A systematic epidemiological investigation would help to describe the natural history of the disease.
In conclusion, the present study confirms the spread of MDR C. auris candidaemia in ICUs across India. Invasive intervention in ICUs may lead to nosocomial acquisition of C. auris infection. As the majority of the isolates are of clonal origin and invasive procedures are risk factors, it is important to study the source of the agent and the transmission mechanism. Until such detailed epidemiological studies are conducted, the providers of critical care in Indian ICUs should be vigilant for C. auris infection in patients with sepsis, especially those with longer ICU stay and antifungal exposure, as these are two important risk factors identified. Rudramurthy et al.
